Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985621 · ClinicalTrials.gov registry record · Phase 3
Tanezumab In Osteoarthritis Of The Hip Or Knee
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT00985621 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 614 participants.
The verdict
NCT00985621, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis
Interventions
- OTHER placebo
- DRUG oxycodone
- BIOLOGICAL tanezumab 10 mg
- BIOLOGICAL tanezumab 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2009-10-30 |
| Est. Completion | 2011-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985621
The ClinicalTrials.gov registry entry for NCT00985621 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00985621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00985621 about?
NCT00985621 is a clinical study titled "Tanezumab In Osteoarthritis Of The Hip Or Knee". The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis
What is the current status of trial NCT00985621?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2009-10-30. Estimated completion is 2011-02-04.
What interventions are being tested in trial NCT00985621?
The interventions under investigation include: placebo (OTHER), oxycodone (DRUG), tanezumab 10 mg (BIOLOGICAL), tanezumab 5 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00985621?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.